Appointment of New CEO

• Deborah Waterhouse appointed as CEO and Managing Director of CSL from 1 February 2027
• Extensive global search process conducted by CSL's Board of Directors
• Ms Waterhouse has over 25 years of experience in managing global specialty pharma companies
• She will retain her base in the U.K. and spend significant time in Australia, the U.S. and CSL's major markets

The Board of Directors of CSL Limited (ASX:CSL; USOTC:CSLLY) has appointed Deborah Waterhouse as Chief Executive Officer and Managing Director, effective from 1 February 2027. Waterhouse is a seasoned leader with extensive experience in managing complex global specialty pharma companies across the U.S., the U.K., continental Europe, and Australia. Since 2017, she has been the CEO of ViiV Healthcare, a joint venture majority-owned by GSK. Waterhouse has also held several senior executive positions at GSK, including leading its U.S. vaccines business and U.S. Primary Care business. Gordon Naylor will continue as Interim CEO until the transition on 1 February 2027.